<code id='621E37A64C'></code><style id='621E37A64C'></style>
    • <acronym id='621E37A64C'></acronym>
      <center id='621E37A64C'><center id='621E37A64C'><tfoot id='621E37A64C'></tfoot></center><abbr id='621E37A64C'><dir id='621E37A64C'><tfoot id='621E37A64C'></tfoot><noframes id='621E37A64C'>

    • <optgroup id='621E37A64C'><strike id='621E37A64C'><sup id='621E37A64C'></sup></strike><code id='621E37A64C'></code></optgroup>
        1. <b id='621E37A64C'><label id='621E37A64C'><select id='621E37A64C'><dt id='621E37A64C'><span id='621E37A64C'></span></dt></select></label></b><u id='621E37A64C'></u>
          <i id='621E37A64C'><strike id='621E37A64C'><tt id='621E37A64C'><pre id='621E37A64C'></pre></tt></strike></i>

          focus

          focus

          author:hotspot    Page View:55693

          Is no one safe from the FTC? Has Pfizer bottomed out? And is biotech finally back?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we delve into the fallout over the FTC’s move to block what looked like a humdrum biotech deal between Sanofi and Maze Therapeutics, a surprising twist that leaves an unanswered question. We also discuss the latest news in the life sciences, including Pfizer’s downbeat future, Vertex Pharmaceuticals’ next big thing, and a newly minted biotech VC with a very famous name.

          advertisement

          For more on what we cover, here’s the FTC news; here’s more from Maze Therapeutics; here’s the Pfizer news; here’s the latest on Vertex; here’s the story behind its pain drug; here’s the Reed Jobs profile; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          Wikipedia

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Long Covid research funding gets a major boost from NIH
          Long Covid research funding gets a major boost from NIH

          NIHgaveaprojecttostudyandfindtreatmentsforlongCovidmoremoneythisweek.AdobeWASHINGTON—TheBidenadminis

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          Abbott's new heart device gets FDA advisory panel nod

          ThedeviceiscalledtheTriClip,anditaddressesadiseasecalledtricuspidregurgitation:aheartconditionthatca